Legionnaire Disease Testing Market

Legionnaire Disease Testing Market Outlook

The legionnaire disease testing market is projected to register a CAGR of 9% during the forecast period, up from USD 292 Million in 2022 to reach a valuation of USD 819.5 Million by 2032.

The legionnaire disease testing market is anticipated to show promising growth prospects during the forecast period as a result of growing competition. New competitors are offering a variety of options at reasonable pricing to fulfil the demand for legionnaire disease testing making it more accessible to customers in the global legionnaire disease testing market.

Report Attribute	Details
Estimated Base Year Value (2021)	USD 267 Million
Expected Market Value (2022)	USD 292 Million
Anticipated Forecast Value (2032)	USD 819.5 Million
Projected Growth Rate (2022 to 2032)	9% CAGR

Sales of legionnaire disease testing are expected to rise significantly. In addition to this, sales of legionnaire disease testing are rising on account for USD 411.3 Million by 2026. Increasing sales of legionnaire disease testing  are also projected to contribute to the growth of the legionnaire disease testing market share.

Increasing public knowledge about effective illness detection and management has resulted from increased government programmes and financing. Furthermore, the worldwide legionnaire disease testing market is being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.

The legionnaire illness testing market may expand as the adoption rate of legionnaire disease testing rises. The legionnaire disease testing market is also predicted to rise due to increased R&D initiatives for technology development for different illnesses.

The shortage of qualified specialists, on the other hand, is likely to stifle the legionnaire disease testing market expansion. Lack of resources and ignorance about infection are also predicted to stymie the sales of legionnaire disease testing market expansion.

Manufacturers in the legionnaire disease testing market get a big platform from which to serve the whole demand for legionnaire disease testing. The worldwide sales of legionnaire disease testing is seeing increased competition. With growing competition, new competitors are offering a variety of options at reasonable pricing, fulfilling the demand for legionnaire disease testing more accessible to customers.

Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.

What are the Key Drivers to the Legionnaire Disease Testing Market Share

According to the World Health Organization, 75-80% of the population is 50 years old or older, with 65-70% of the population being male. The male population is more susceptible to the demand for legionnaire disease testing than the female population.

Furthermore, the elderly are at a higher risk of legionnaire disease testing and are more likely to get infected. Globally, however, the advancement of innovative testing technologies is increasing. Increased knowledge of present and evolving technology is also helping to boost acceptance of the new testing method, which is projected to open up significant sales of legionnaire disease testing.

However, a scarcity of qualified healthcare providers, as well as a lack of knowledge of the condition and the inability to diagnose it at an early stage, may stymie the demand for legionnaire disease testing market expansion. Furthermore, the absence of improved healthcare facilities may limit the legionnaire disease testing market growth.

Which is the Leading Region in the Legionnaire Disease Testing Market

The sales of legionnaire disease testing market in Asia-Pacific are predicted to expand rapidly in the next years. This is owing to the existence of a huge population of people who are at high risk. In addition, a lack of knowledge on how to treat infectious diseases is adding to the region's growing population at risk.

The legionnaire disease testing market is predicted to increase rapidly as a result of this. Because of the region's excellent healthcare infrastructure and extensive research and development activities, the North American legionnaire disease testing market is likely to be the most prominent. Due to the availability of qualified researchers and a strong acceptance rate in the area, Europe will rank second in the sales of legionnaire disease testing market.

Due to a scarcity of qualified specialists in the region, the legionnaire disease testing market in Latin America is predicted to rise steadily. Due to a lack of facilities and public knowledge of legionnaire illness, the Middle East and Africa are likely to be the least profitable hence a decline in the demand for legionnaire disease testing.

Who are the Key Players in the Legionnaire Disease Testing Market

The report consists of key players, contributing to the legionnaire disease testing market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analyzes the competitive landscape and legionnaire disease testing market share acquired by players to strengthen their market position.

Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.

Recent developments of the Legionnaire Disease Testing Market

• June 2021 - Phigenics has unveiled a new diagnostic tool. To detect Legionella serogroup and species in building water systems, Phigenics Validation Test (PVT) Next Day LegiPlex PCR (Polymerase Chain Reaction). It provides quick findings, and the test met the International Standards Organization's (ISO) requirements for a limit of detection and specificity.
• March 2021 – IDEXX released the findings of research conducted by WLN, a water quality and technology firm. The IDEXX Legiolert test was compared to the Dutch national reference technique for detecting Legionella pneumophila in the research.
• A two-day free virtual conference on legionnaires' disease hazards during and after a covid-19 pandemic was held by the Alliance to Prevent Legionnaires' Disease, a national nonprofit organisation, in August 2020. This virtual conference aimed to increase public awareness of the effective management of risk factors associated with watery Legionnaires' disease.

Report Scope

Report Attribute	Details
Growth rate	CAGR of 9% from 2022 to 2032
Base year for estimation	2021
Historical data	2015 to 2020
Forecast period	2022 to 2032
Quantitative units	Revenue in USD Million and CAGR from 2022 to 2032
Report coverage	Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered	Product type, diagnostic test, end user, region
Regional scope	North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand
Country scope	USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa
Key companies profiled	Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others
Customization scope	Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail of customized purchase options to meet your exact research needs.

 Key Segments For Legionnaire Disease Testing Market

Legionnaire Disease Testing Segmentation by Product Type:

• Devices
• Polymerase Chain Reaction System
• Sequencer System
• Test Kits
• Assay Based Test Kits
• Rapid Test Kits

Legionnaire Disease Testing Segmentation by Diagnostic Test:

• Culture Method
• Urinary Antigen Test
• Paired Serology
• Direct Fluorescent Antibody (DFA) Stain
• Polymerase Chain Reaction (PCR)
• Combination Testing (Culture and Urinary Antigen Tests)

Legionnaire Disease Testing Segmentation by End User:

• Hospitals
• Diagnostic Laboratories
• Clinical Research Centers
• Academic Institutes
• Research Centers
• Others

Legionnaire Disease Testing Segmentation by Region:

• North America (USA., Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, UK., France, Italy, Spain, Poland, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, Thailand, Malaysia, Vietnam, Indonesia)
• Oceania (Australia, New Zealand)
• Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa)

Frequently Asked Questions

What is the Growth Outlook for the Legionnaire Disease Testing Market?

The legionnaire disease testing market is predicted to register a CAGR of 9% during the forecast period.

Who are the Key Players in the Legionnaire Disease Testing Market?

Key players holding substantial legionnaire disease testing market share include Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others

What is the Future of the Legionnaire Disease Testing Market?

As per the analysis, the legionnaire disease testing market share is likely to be USD 411.3 Million by 2026.

Which is the Key Driver in the Legionnaire Disease Testing Market?

Demand for legionnaire disease testing is likely to rise being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.